Quantitative imaging phenotypic classifier for distinguishing radiation effects from tumor recurrence in glioblastoma .
Active Project Grant Awarded Last action
- Award ID
- R01CA264017
- Recipient
-
University Of Wisconsin System UEI LCLSJAGTNZQ7 Part of University Of Wisconsin System
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $7,293,426
Award facts
- Assistance listing
- 93.394 Cancer Detection and Diagnosis Research
- Completion date 73% complete
- Originally
- Funding
-
- $6,571,504.00 Federal
- $721,922.00 Non-federal
- Place of performance
- Madison, WI 53715, USA
Award details come from USAspending.gov.
Description
- Abstract
- Over 14,000 glioblastoma (GBM) patients annually in the US undergo a combination of cranial surgery, chemotherapy, and radiation as standard treatment for their aggressive cancer. Unfortunately, ~40% of these patients will be identified with a suspicious lesion on a post-chemo-radiation follow up MRI scan (T1W, T2W, flair). A significant challenge in the management of GBM tumors is the differentiation of these lesions as tumor recurrence or benign treatment-related radiation effects (TRRE). These conditions mimic each other, clinically and radiographically. Unfortunately, in the absence of reliable diagnostic tools, patients with TRRE will undergo an unnecessary and avoidable invasive stereotactic brain biopsy (ST-BX) for confirmation of disease absence. However, even the invasive ST-BX has an accuracy of 85-90% due to sampling errors associated with obtaining a biopsy tissue which may not be representative of the underlying disease pathology. Consequently, building non-invasive decision support tools which yield a diagnostic accuracy that is non-inferior to ST-BX, represents an attractive solution for obviating unnecessary intra-cranial ST-BX in patients with benign radiation effects. Our group has developed a new image-based recurrence risk classifier (IRRISC) using routine MRI scans, that has demonstrated an accuracy of 85% in distinguishing tumor recurrence from TRRE, on N=58 studies. Our initial set of IRRISC features comprise disorder in gradient orientations on gadolinium (GD)-T1W MRI which have been shown to be significantly higher in tumor recurrence compared to TRRE. Interestingly, we have recently also demonstrated that construction of separate classifiers for males and females yielded significantly improved prognosis of GBM survival compared to an 'all-comers' model. In this R01 project, we seek to further improve and validate the accuracy of IRRISC by expanding our initial feature set (using GD-T1W MRI) to include (1) additional features from anatomical (T2W, flair) and functional MR sequences (PERFUSION), (2) a new class of biophysical deformation attributes from "normal" brain parenchyma, and (3) construction of SEX-specific models to exploit sexual-dimorphism in GBM, for distinguishing tumor recurrence from TRRE. Overcoming limitations of previous work pertaining to small samples and lack of histopathological validation, our work will utilize the largest multi-institutional histopathologically confirmed cohort till date of N=470 studies of TRRE and tumor recurrence, to harmonize and validate IRRISC. Further we will establish the biological underpinning of our IRRISC features by evaluating their association with histopathological hallmarks of TRRE and tumor recurrence. Finally, IRRISC will be validated as decision support in a machine-reader study at 3 clinical sites. Criteria for success for IRRISC is that IT will (a) be non-inferior to the accuracy of ST-BX (~85-90%), and (B) identify no more than 50% of patients with TRRE as having cancer. These criteria will ensure that IRRISC is clinically actionable as a robust and reliable classifier, by obviating at least 50% of unnecessary intra-cranial biopsies in patients with TRRE, while also maintaining a high true positive rate for cancer recurrence.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | $710,498 | $0 | |
| Amendment | $724,184 | $0 | |
| Amendment | $724,184 | $0 | |
| Amendment | $724,184 | $0 | |
| Amendment | $72,192 | $0 | |
| Amendment | -$72,192 | $0 | |
| Amendment | $72,192 | $0 | |
| Amendment | -$72,192 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $761,344 | $0 | |
| Amendment | $761,344 | $0 | |
| Amendment | -$649,730 | $0 | |
| Amendment | $649,730 | $0 | |
| Amendment | $649,730 | $0 | |
| Amendment | -$649,730 | $0 | |
| Amendment | $649,730 | $0 | |
| Amendment | -$649,730 | $0 | |
| Amendment | $721,922 | $0 | |
| Amendment | $721,922 | $721,922 | |
| Original award | $721,922 | $0 |
Show all 24
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| Baptist Health South Florida, Inc. | $78,521 | |
| Cleveland Clinic Lerner College Of Medicine Of Case Western Reserve University | $131,336 | |
| Emory University | $30,089 | |
| GE Medical Systems Information Technologies, Inc. | $425,194 | |
| Case Western Reserve University | $204,249 | |
| General Electric Company | $51,166 | |
| Northwestern University | $75,565 |
Quick answers
Who received award R01CA264017?
R01CA264017 was awarded to University Of Wisconsin System by National Cancer Institute (National Institutes of Health) on June 30, 2022.
How much is award R01CA264017 worth?
$7,293,426 has been obligated on R01CA264017: $6,571,504 in federal funding and $721,922 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award